Stepstone Group Lp Exits Position in Trevena Inc (TRVN)

Trevena Inc (TRVN) : Stepstone Group Lp has sold out all of its stake in Trevena Inc during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 1,996 shares of Trevena Inc which is valued at $13,613.

Other Hedge Funds, Including , Vanguard Group Inc boosted its stake in TRVN in the latest quarter, The investment management firm added 82,637 additional shares and now holds a total of 1,228,164 shares of Trevena Inc which is valued at $8.4 Million.Cornerstone Capital Management Holdings. reduced its stake in TRVN by selling 1,400 shares or 16.09% in the most recent quarter. The Hedge Fund company now holds 7,300 shares of TRVN which is valued at $49,786.Blackrock Investment Management boosted its stake in TRVN in the latest quarter, The investment management firm added 647 additional shares and now holds a total of 114,460 shares of Trevena Inc which is valued at $780,617.Swiss National Bank boosted its stake in TRVN in the latest quarter, The investment management firm added 10,000 additional shares and now holds a total of 56,000 shares of Trevena Inc which is valued at $434,000.

Trevena Inc opened for trading at $7.03 and hit $7.19 on the upside on Wednesday, eventually ending the session at $7.02, with a gain of 0.72% or 0.05 points. The heightened volatility saw the trading volume jump to 3,59,375 shares. Company has a market cap of $366 M.

Many Wall Street Analysts have commented on Trevena Inc. Company shares were Reiterated by FBR Capital on May 17, 2016 to “Outperform”, Firm has raised the Price Target to $ 16 from a previous price target of $13 .Shares were Reiterated by Needham on May 17, 2016 to “Buy” and Lowered the Price Target to $ 11 from a previous price target of $14 .FBR Capital Initiated Trevena Inc on Mar 29, 2016 to “Outperform”, Price Target of the shares are set at $16.

Trevena Inc. (Trevena) is a clinical-stage biopharmaceutical company. The Company discovers develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform the Company has identified and advanced three differentiated product candidates: TRV130 a small molecule G protein biased ligand at the mu-opioid receptor to treat patients experiencing moderate to severe acute pain where IV administration is preferred; TRV734 a small molecule G protein biased ligand at the mu-opioid receptor to treat moderate to severe acute and chronic pain and TRV027 a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R) inhibiting G protein signaling and activating b-arrestin signaling. The Company has also identified a new product candidate TRV250 a small molecule G protein biased ligand of the delta-opioid receptor program focused on central nervous system (CNS).

Leave a Reply

Trevena Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Trevena Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.